Core Viewpoint - Skye Bioscience, Inc. announced promising preclinical data for its CB1 antibody, nimacimab, indicating significant weight loss in a murine diet-induced obesity model, suggesting potential as a treatment for obesity and metabolic disorders [1][2][5] Group 1: Preclinical Data and Efficacy - Nimacimab demonstrated effective weight loss in a diet-induced obesity model after 25 days of treatment, showing a 23.5% weight loss when used alone, comparable to monlunabant and tirzepatide [5] - When combined with tirzepatide, nimacimab achieved greater than 30% weight loss, indicating an additive effect [5] - The study highlighted that nimacimab's weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers [1][5] Group 2: Mechanism of Action - Nimacimab employs a non-competitive allosteric binding mechanism to the CB1 receptor, which may provide advantages over small molecules like monlunabant that compete for the receptor's active site [3][7] - In vitro data showed that nimacimab's potency remained stable even at higher concentrations of CB1 agonists, while monlunabant's potency significantly decreased under similar conditions [6][9] - The differentiated mechanism of nimacimab aims to achieve weight loss benefits without the neuropsychiatric side effects associated with current small molecule CB1 inhibitors [7][10] Group 3: Future Developments - Skye anticipates initial data from its Phase 2a study in obesity to be available in late Q3 or early Q4 2025, which will further assess nimacimab's efficacy [2][5] - The company is conducting a Phase 2 clinical trial to evaluate nimacimab's effects both as a monotherapy and in combination with GLP-1 receptor agonists [10]
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model